PMID- 32504832
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20210706
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 159
DP  - 2020 Sep
TI  - Tumor microenvironment-related dendritic cell deficiency: a target to enhance 
      tumor immunotherapy.
PG  - 104980
LID - S1043-6618(20)31288-3 [pii]
LID - 10.1016/j.phrs.2020.104980 [doi]
AB  - Dendritic cells (DCs), as specialized antigen-presenting cells, are essential for 
      the initiation of specific T cell responses in innate antitumor immunity and, in 
      certain cases, support humoral responses to inhibit tumor development. Mounting 
      evidence suggests that the DC system displays a broad spectrum of dysfunctional 
      status in the tumor microenvironment (TME), which ultimately affects antitumor 
      immune responses. DC-based therapy can restore the function of DCs in the TME, 
      thus showing a promising potential in tumor therapy. In this review, we provide 
      an overview of the DC deficiency caused by various factors in the TME and discuss 
      proposed strategies to reverse DC deficiency and the applications of novel 
      combinatorial DC-based therapy for immune normalization of the tumor.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Zhu, Shan
AU  - Zhu S
AD  - Institute of Translational Medicine, The First Hospital of Jilin University, 
      Changchun, China.
FAU - Yang, Ning
AU  - Yang N
AD  - Institute of Translational Medicine, The First Hospital of Jilin University, 
      Changchun, China.
FAU - Wu, Jing
AU  - Wu J
AD  - Institute of Translational Medicine, The First Hospital of Jilin University, 
      Changchun, China.
FAU - Wang, Xue
AU  - Wang X
AD  - Institute of Translational Medicine, The First Hospital of Jilin University, 
      Changchun, China.
FAU - Wang, Wan
AU  - Wang W
AD  - Institute of Translational Medicine, The First Hospital of Jilin University, 
      Changchun, China.
FAU - Liu, Yong-Jun
AU  - Liu YJ
AD  - Sanofi R&D, Cambridge, MA, USA.
FAU - Chen, Jingtao
AU  - Chen J
AD  - Institute of Translational Medicine, The First Hospital of Jilin University, 
      Changchun, China. Electronic address: jtchen@jlu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200603
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Cancer Vaccines)
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/therapeutic use
MH  - Dendritic Cells/drug effects/*immunology/metabolism/transplantation
MH  - Humans
MH  - Immune Checkpoint Inhibitors/therapeutic use
MH  - Immunotherapy
MH  - Neoplasms/*immunology/metabolism/pathology/therapy
MH  - *Tumor Escape/drug effects
MH  - *Tumor Microenvironment
OTO - NOTNLM
OT  - DC-based therapy
OT  - Dendritic cells
OT  - Dysfunction
OT  - Tumor microenvironment
EDAT- 2020/06/07 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/01/23 00:00 [received]
PHST- 2020/05/07 00:00 [revised]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
PHST- 2020/06/07 06:00 [entrez]
AID - S1043-6618(20)31288-3 [pii]
AID - 10.1016/j.phrs.2020.104980 [doi]
PST - ppublish
SO  - Pharmacol Res. 2020 Sep;159:104980. doi: 10.1016/j.phrs.2020.104980. Epub 2020 
      Jun 3.